Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance

Pt(IV) prodrug 2 highly accumulate in cancer cells than normal ones and activated by endogenous reducing molecules to release cisplatin and indomethacin simultaneously, exhibiting selective inhibition to cancer cell lines and sensitivity to cisplatin-resistant cancer cells. Moreover, this prodrug reduces the invasiveness of tumor cells and disrupts capillary-like tube formation.70